Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and MedinCell announced that the U.S. Food and Drug Administration has approved UZEDY, or risperidone, extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq, a copolymer technology proprietary to MedinCell that controls the steady release of risperidone. Therapeutic blood concentrations are reached within 6-24 hours of a single dose. UZEDY will be available in the U.S. in the coming weeks.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TEVA:
- Teva falls -8.4%
- Teva falls -8.7%
- Teva discloses FDA Complete Response Letter to partner Alvotech for AVT02
- Teva call volume above normal and directionally bullish
- Teva’s CP trial failure may add some risk for Neurocrine, says RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com